EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy

Stephen L Wang, Timothy A Chan

Cancer Cell · 2025-04 · 43 (4) · 641-664

DOI: 10.1016/j.ccell.2025.03.006 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Cell, 2025-04. Verfasst von Stephen L Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA; Medical Scientist Training Program, Case Western Reserv…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 276 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, National Institutes of Health National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have improved outcomes of patients with many different cancers. These antibodies target molecules such as programmed cell death 1 (PD-1) or cytotoxic T lymphocyte associated protein 4 (CTLA-4) which normally function to limit immune activity. Treatment with ICIs reactivates T cells to destroy tumor cells in a highly specific manner, which in some patients, results in dramatic remissions and durable disease control. Over the last decade, much effort has been directed at characterizing factors that drive efficacy and resistance to ICI therapy. Food and Drug Administration (FDA)-approved biomarkers for ICI therapy have facilitated more judicious treatment of cancer patients and transformed the field of precision oncology. Yet, adaptive immunity against cancers is complex, and newer data have revealed the potential utility of other biomarkers. In this review, we discuss the utility of currently approved biomarkers and highlight how emerging biomarkers can further improve the identification of patients who benefit from ICIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasmsBiomarkers, TumorHumansCTLA-4 AntigenProgrammed Cell Death 1 Receptor

Substanzen

Immune Checkpoint InhibitorsBiomarkers, TumorCTLA-4 AntigenProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA; Medical Scientist Training Program, Case Western Reserve University School of Medicine, Cleveland, OH, USA; Department of Gen…
  • Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA; National Center for Regenerative Medicine, Cleveland, OH, USA. Electronic address: chant2@ccf.org.

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • National Institutes of Health National Cancer Institute
  • California Community Foundation
  • National Institutes of Health
  • NIH National Institute of General Medical Sciences

Zitieren

APA

Wang, S. L., & Chan, T. A. (2025). Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy. Cancer Cell, 43(4), 641-664. https://doi.org/10.1016/j.ccell.2025.03.006

Vancouver

Wang SL, Chan TA. Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy. Cancer Cell. 2025;43(4):641-664. doi:10.1016/j.ccell.2025.03.006

BibTeX
@article{Wang2025,
  author = {Wang, Stephen L and Chan, Timothy A},
  title = {Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy},
  journal = {Cancer Cell},
  year = {2025},
  volume = {43},
  number = {4},
  pages = {641--664},
  doi = {10.1016/j.ccell.2025.03.006}
}
Kostenlos starten →